Design Therapeutics, Inc. DSGN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s additional paid-in capital?
- Design Therapeutics, Inc. (DSGN) reported additional paid-in capital of $532.96M in Q1 2026.
- How has Design Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Design Therapeutics, Inc.'s additional paid-in capital increased by 12.8% year-over-year, from $472.39M to $532.96M.
- What is the long-term trend for Design Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s additional paid-in capital has grown at a 307.9% compound annual growth rate (CAGR), from $451K to $509.1M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.